{"groups":[{"description":"Liposarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Cohort 1"},{"description":"Leiomyosarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"FG001","title":"Cohort 2"},{"description":"Undifferentiated Sarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"FG002","title":"Cohort 3"},{"description":"Malignant Peripheral Nerve Sheath Tumor patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"FG003","title":"Cohort4"},{"description":"Other Sarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"FG004","title":"Cohort 5"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"29"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"29"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"From August 2012 to April 2014, a total of 72 patients were accrued to this study (Cohort 1 - 12, Cohort 2 - 10, Cohort 3 - 11, Cohort 4 - 10 Cohort 5 - 29) at a rate of 4.5 patients per month."}